Fidaxomicin for Clostridium difficile Infection.

Fidaxomicin (Dificid) for Clostridium difficile infection.

Volume 87, Number 3 www.aafp.org/afp American Family Physician 211 Fidaxomicin (Dificid) is an oral macrolide antibiotic labeled for the treatment of Clostridium difficile–associated diarrhea in adults. It primarily exhibits activity against species of clostridia, mainly C. difficile, while having no or limited activity against normal gastrointestinal flora. It joins the standard treatments of ...

Fidaxomicin is a Superior Treatment to Vancomycin for Recurrent Clostridium Difficile Infection

467Analysis of Clinical and Economical Outcomes of Fidaxomicin Use for Clostridium difficile infections

A case report of successful management of clostridium difficile colitis with antegrade Fidaxomicin through a mucous fistula obviating the need for subtotal colectomy

INTRODUCTION Clostridium difficile is the most common cause of healthcare-associated infections and can have devastating morbidity and mortality. Traditional treatment algorithms involve intravenous metronidazole and enteric metronidazole or vancomycin. Fidaxomicin (DificidR) targets "switch regions" within RNA polymerases and effectively kills clostridium difficile bacteria and is typically ad...

SMT19969 for Clostridium difficile infection (CDI): in vivo efficacy compared with fidaxomicin and vancomycin in the hamster model of CDI

OBJECTIVES SMT19969 is a novel narrow-spectrum antimicrobial under development for the treatment of Clostridium difficile infection (CDI). The objectives were to assess the relative efficacies of SMT19969, vancomycin and fidaxomicin in the hamster model of CDI. METHODS Hamsters were infected with either C. difficile BI1 (ribotype 027) or C. difficile 630 (ribotype 012) prior to treatment with...

Safety Analysis of Fidaxomicin in Comparison With Oral Vancomycin for Clostridium difficile Infections

Fidaxomicin is a novel macrocyclic antibiotic recently approved by the US Food and Drug Administration for the treatment of Clostridium difficile-associated diarrhea in adults. We reviewed safety data from nonclinical studies and clinical trials (phases 1, 2A, and 3) with fidaxomicin. In nonclinical studies, fidaxomicin was administered orally at approximately 1 g/kg/d to dogs for up to 3 month...